Practice
Open Access
Inclusion body myositis
Jodi Warman-Chardon, Ari Breiner and Pierre R. Bourque
CMAJ April 15, 2024 196 (14) E486; DOI: https://doi.org/10.1503/cmaj.231815
Jodi Warman-Chardon
Ottawa Hospital Research Institute (Warman-Chardon, Breiner, Bourque); Department of Medicine, Neurology (Warman-Chardon, Breiner, Bourque), The Ottawa Hospital, Ottawa, Ont.
MDAri Breiner
Ottawa Hospital Research Institute (Warman-Chardon, Breiner, Bourque); Department of Medicine, Neurology (Warman-Chardon, Breiner, Bourque), The Ottawa Hospital, Ottawa, Ont.
MDPierre R. Bourque
Ottawa Hospital Research Institute (Warman-Chardon, Breiner, Bourque); Department of Medicine, Neurology (Warman-Chardon, Breiner, Bourque), The Ottawa Hospital, Ottawa, Ont.
MDArticle Figures & Tables
There are no figures or tables available.
In this issue
Article tools
Respond to this article
Inclusion body myositis
Jodi Warman-Chardon, Ari Breiner, Pierre R. Bourque
CMAJ Apr 2024, 196 (14) E486; DOI: 10.1503/cmaj.231815
Jump to section
- Article
- Inclusion body myositis is the most common type of late-onset inflammatory myopathy
- Typical features are insidious, painless, and progressive weakness and muscle atrophy that is asymmetric and multifocal
- Electromyography (EMG) and muscle biopsy are the leading diagnostic tools
- Differential diagnosis includes motor neuron disease, other inflammatory myopathies, and late-onset muscular dystrophies
- Treatment is supportive
- Footnotes
- References
- Figures & Tables
- Related Content
- Responses
- Metrics
Related Articles
Cited By...
- No citing articles found.